Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Dolutegravir | Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. Group: Biochemicals. Alternative Names: (4R, 12aS)-N-[(2, 4-Difluorophenyl)methyl]-3, 4, 6, 8, 12, 12a-hexahydro-7-hydroxy-4-methyl-6, 8-dioxo-2H-pyrido[1', 2':4, 5]pyrazino[2, 1-b][1, 3]oxazine-9-carboxamide; GSK 1349572; S/GSK1349572. Grades: Highly Purified. CAS No. 1051375-16-6. Pack Sizes: 5mg, 10mg, 25mg. Molecular Formula: C20H19F2N3O5, Molecular Weight: 419.38. US Biological Life Sciences. |  Worldwide |
| Dolutegravir | Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC 50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC 50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC 50 =3.6-5.8 nM) [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: S/GSK1349572. CAS No. 1051375-16-6. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-13238. |  |
| Dolutegravir (GSK1349572) | Dolutegravir is a two-metal-binding HIV-1 integrase inhibitor with IC50 of 2.7 nM, with modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. It blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). Synonyms: GSK-1349572; GSK 1349572; GSK1349572; Tivicay. Grades: ≥98%. CAS No. 1051375-16-6. Molecular formula: C20H19F2N3O5. Mole weight: 419.38. |  |
| Dolutegravir Impurity 25 | Dolutegravir Impurity 25. Uses: For analytical and research use. Group: Impurity standards. Alternative Names: (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid. CAS No. 1246616-73-8. Molecular formula: C13H14N2O6. Mole weight: 294.09. Catalog: APB1246616738. |  |
| Dolutegravir Impurity 7 | Dolutegravir Impurity 7. Uses: For analytical and research use. Group: Impurity standards. Alternative Names: (4R,12aS)-N-(4-fluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide. CAS No. 1863916-88-4. Molecular formula: C20H20FN3O5. Mole weight: 401.39. Catalog: APB1863916884. | |
| Dolutegravir Impurity 8 | Dolutegravir Impurity 8. Uses: For analytical and research use. Group: Impurity standards. Alternative Names: (4R,12aS)-N-(2-fluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide. CAS No. 1863916-87-3. Molecular formula: C20H20FN3O5. Mole weight: 401.39. Catalog: APB1863916873. | |
| Dolutegravir sodium | Dolutegravir sodium salt is a HIV integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. Uses: Hiv integrase inhibitors. Synonyms: DTG; GSK1349572; GSK 1349572; GSK-1349572. Grades: >98%. CAS No. 1051375-19-9. Molecular formula: C20H18F2N3NaO5. Mole weight: 441.36. | |
| Dolutegravir sodium | Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC 50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC 50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC 50 =3.6-5.8 nM) [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: S/GSK1349572 sodium. CAS No. 1051375-19-9. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13238A. | |
| Dolutegravir (Sodium Salt) | Dolutegravir (Sodium Salt). Uses: For analytical and research use. Group: Impurity standards. Alternative Names: sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate. CAS No. 1051375-19-9. Molecular formula: C20H18F2N3O5·Na. Mole weight: 443.38. Catalog: APB1051375199. | |
| 1-(2,2-Dimethoxyethyl)-1,4-dihydro-4-oxo-2,5-pyridinedicarboxylic Acid 2,5-Diethyl Ester | 1-(2,2-Dimethoxyethyl)-1,4-dihydro-4-oxo-2,5-pyridinedicarboxylic Acid 2,5-Diethyl Ester is an intermediate used in the synthesis of Defluoro Dolutegravir (D228715), which is an impurity of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. Group: Biochemicals. Grades: Highly Purified. CAS No. 1246616-75-0. Pack Sizes: 5mg, 10mg. Molecular Formula: C15H21NO7, Molecular Weight: 327.33. US Biological Life Sciences. | Worldwide |
| 1-(2,3-Dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic Acid | 1-(2,3-Dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic Acid is an intermediate in the synthesis of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Group: Biochemicals. Grades: Highly Purified. CAS No. 1206102-06-8. Pack Sizes: 10mg, 25mg. Molecular Formula: C16H17NO6. US Biological Life Sciences. | Worldwide |
| 1-(2,3-Dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic Acid Methyl Ester | 1-(2,3-Dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic Acid Methyl Ester is an intermediate in the synthesis of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Group: Biochemicals. Grades: Highly Purified. CAS No. 1206102-07-9. Pack Sizes: 10mg, 25mg. Molecular Formula: C17H19NO6, Molecular Weight: 333.34. US Biological Life Sciences. | Worldwide |
| 2-[(1E)-2-Phenylethenyl]-3-(phenylmethoxy)-4H-pyran-4-one | 2-[(1E)-2-Phenylethenyl]-3-(phenylmethoxy)-4H-pyran-4-one is an intermediate in the synthesis of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Group: Biochemicals. Grades: Highly Purified. CAS No. 1206102-05-7. Pack Sizes: 25mg, 100mg. Molecular Formula: C20H16O3. US Biological Life Sciences. | Worldwide |
| 3-Benzyloxy-2-(2-hydroxy-2-phenylethyl)-4H-pyran-4-one | 3-Benzyloxy-2-(2-hydroxy-2-phenylethyl)-4H-pyran-4-one is an intermediate in the synthesis of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Group: Biochemicals. Grades: Highly Purified. CAS No. 1206102-04-6. Pack Sizes: 25mg, 50mg. Molecular Formula: C20H18O4. US Biological Life Sciences. | Worldwide |
| 3-Bromo-1-(2,2-dimethoxyethyl)-1,4-dihydro-4-oxo-2,5-pyridinedicarboxylic Acid 2,5-Diethyl Ester | 3-Bromo-1-(2,2-dimethoxyethyl)-1,4-dihydro-4-oxo-2,5-pyridinedicarboxylic Acid 2,5-Diethyl Ester is an intermediate in the synthesis of Defluoro Dolutegravir (D228715). Defluoro Dolutegravir is an impurity of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. Group: Biochemicals. Grades: Highly Purified. CAS No. 1246616-76-1. Pack Sizes: 2.5mg, 5mg. Molecular Formula: C15H20BrNO7, Molecular Weight: 406.23. US Biological Life Sciences. | Worldwide |
| 3-Bromo-1,4-dihydro-4-oxo-1-(2-oxoethyl)-2,5-pyridinedicarboxylic Acid 2,5-Diethyl Ester | 3-Bromo-1,4-dihydro-4-oxo-1-(2-oxoethyl)-2,5-pyridinedicarboxylic Acid 2,5-Diethyl Ester is an intermediate in the synthesis of Defluoro Dolutegravir (D228715). Defluoro Dolutegravir is an impurity of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. Group: Biochemicals. Grades: Highly Purified. CAS No. 1246616-77-2. Pack Sizes: 1mg, 2.5mg. Molecular Formula: C13H14BrNO6, Molecular Weight: 360.16. US Biological Life Sciences. | Worldwide |
| Bictegravir | Bictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM for strand transfer activity. Bictegravir is a drug of the integrase inhibitor class that was copied from Dolutegravir by scientists at Gilead Sciences. Bictegravir also inhibits HIV-1 viral infection in MT-2 and MT-4 cells, CD4+ T cells, and macrophages (EC50s = 1.5, 2.5, 1.5, and 6.6 nM, respectively) without exhibiting cytotoxicity (CC50s = 10.3, 3.7, 13, and 29.8 μM, respectively). In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection. Synonyms: GS-9883; GS 9883; GS9883. Grades: ≥98%. CAS No. 1611493-60-7. Molecular formula: C21H18F3N3O5. Mole weight: 449.39. | |
| Bictegravir sodium | Bictegravir sodium is a HIV-1 integrase strand transfer inhibitor that is derived from the drug dolutegravir. Synonyms: Bictegravir sodium|1807988-02-8|Bictegravir (sodium)|UNII-4L5MP1Y7W7|4L5MP1Y7W7|sodium;(1S, 11R, 13R)-3, 6-dioxo-7-[(2, 4, 6-trifluorophenyl)methylcarbamoyl]-12-oxa-2, 9-diazatetracyclo[11.2.1.02, 11.04, 9]hexadeca-4, 7-dien-5-olate|Bictegravir sodium [USAN]|Bictegravir sodium (JAN / USAN) |CHEMBL3989867|SCHEMBL 19991461|CHEBI: 172961|BCP20910|HY-17605A|AC-30681|CS-0380750|D10910|N16970|A904622|Q27259 952|GS-9883; GS 9883; GS9883; GS-9883-01; GS9883-01; GS 9883-01|(2R,5S,13aR)-8-Hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide monosodium salt|2,5-Methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-, sodium salt (1:1), (2R,5S,13aR)-|Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1, 3]oxazepin-8-olate|sodium (2R,5S,13aR)-7,9-dioxo-10-[(2,4,6-trifluorobenzyl)carbamoyl]-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate. Grades: >98%. CAS No. 1807988-02-8. Molecular formula: C21H17F3N3NaO5. Mole weight: 471.4. | |
Our database is helping our users find suppliers everyday.
